Davide Seripa

List of Publications by Year
in descending order

242 papers	16,634 citations	23567 58 h-index	19190 118 g-index
249 all docs	249 docs citations	249 times ranked	20772 citing authors

#	Article	IF	Citations
1	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	21.4	2,155
2	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
3	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
4	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
5	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 2011, 16, 903-907.	7.9	529
6	Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?. American Journal of Geriatric Psychiatry, 2010, 18, 98-116.	1.2	502
7	Development and Validation of a Multidimensional Prognostic Index for One-Year Mortality from Comprehensive Geriatric Assessment in Hospitalized Older Patients. Rejuvenation Research, 2008, 11, 151-161.	1.8	397
8	Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Research Reviews, 2010, 9, 399-417.	10.9	292
9	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimerâ€™s Disease and Late-Life Cognitive Disorders: A Systematic Review. Journal of Alzheimer's Disease, 2017, 59, 815-849.	2.6	249
10	Diet and Alzheimerâ€™s disease risk factors or prevention: the current evidence. Expert Review of Neurotherapeutics, 2011, 11, 677-708.	2.8	231
11	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. Journal of Alzheimer's Disease, 2018, 62, 993-1012.	2.6	214
12	Prevalence, Clinical Features and Avoidability of Adverse Drug Reactions as Cause of Admission to??a??Geriatric Unit. Drug Safety, 2008, 31, 545-556.	3.2	181
13	Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimerâ€™s disease pathology. Progress in Lipid Research, 2011, 50, 313-330.	11.6	172
14	Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. Journal of Medical Genetics, 2003, 40, 704-708.	3.2	165
15	Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drugâ€“Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms. Gastroenterology, 2007, 133, 465-471.	1.3	161
16	Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review. Journal of Nutrition, Health and Aging, 2015, 19, 313-328.	3.3	154
17	Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 22, 715-740.	2.6	149
18	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. Alzheimer's and Dementia, 2013, 9, 113-122.	0.8	140

#	Article	IF	Citations
19	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
20	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 21, 691-724.	2.6	139
21	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimerâ€™s Disease. BioMed Research International, 2016, 2016, 1-15.	1.9	138
22	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. Journal of the American Medical Directors Association, 2017, 18, 89.e1-89.e8.	2.5	126
23	Amyloidâ€Î² immunotherapy for alzheimer disease: Is it now a long shot?. Annals of Neurology, 2019, 85, 303-315.	5.3	126
24	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4, 213-238.	2.0	121
25	Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors. Clinical Cancer Research, 2004, 10, 5349-5354.	7.0	119
26	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. Rejuvenation Research, 2015, 18, 389-412.	1.8	112
27	Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid. Current Alzheimer Research, 2010, 7, 40-55.	1.4	109
28	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. Journal of Alzheimer's Disease, 2015, 47, 793-813.	2.6	108
29	Clinical Features of Reflux Esophagitis in Older People: A Study of 840 Consecutive Patients. Journal of the American Geriatrics Society, 2006, 54, 1537-1542.	2.6	107
30	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Molecular Psychiatry, 2013, 18, 461-470.	7.9	103
31	Alcohol Drinking, Cognitive Functions in Older Age, Predementia, and Dementia Syndromes. Journal of Alzheimer's Disease, 2009, 17, 7-31.	2.6	98
32	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. International Journal of Geriatric Psychiatry, 2012, 27, 1218-1238.	2.7	90
33	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. American Journal of Geriatric Psychiatry, 2017, 25, 1236-1248.	1.2	90
34	Therapeutic intervention for Alzheimer's disease with Î³-secretase inhibitors: still a viable option?. Expert Opinion on Investigational Drugs, 2011, 20, 325-341.	4.1	86
35	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging, 2011, 32, 756.e11-756.e15.	3.1	82
36	Oxidative balance, homocysteine, and uric acid levels in older patients with Late Onset Alzheimer's Disease or Vascular Dementia. Journal of the Neurological Sciences, 2014, 337, 156-161.	0.6	82

#	Article	IF	Citations
37	The Genetics of the Human APOE Polymorphism. Rejuvenation Research, 2011, 14, 491-500.	1.8	81
38	Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke. Stroke, 1998, 29, 399-403.	2.0	80
39	Solanezumab for the treatment of mild-to-moderate Alzheimerâ€™s disease. Expert Review of Clinical Immunology, 2012, 8, 135-149.	3.0	79
40	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	2.6	78
41	The Multidimensional Prognostic Index (MPI), Based on a Comprehensive Geriatric Assessment Predicts Short- and Long-Term Mortality in Hospitalized Older Patients with Dementia. Journal of Alzheimer's Disease, 2009, 18, 191-199.	2.6	77
42	Understanding the Amyloid Hypothesis in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 493-510.	2.6	77
43	Different models of frailty in predementia and dementia syndromes. Journal of Nutrition, Health and Aging, 2011, 15, 711-719.	3.3	76
44	Neuropsychiatric Symptoms and Functional Status in Alzheimerâ€™s Disease and Vascular Dementia Patients. Current Alzheimer Research, 2012, 9, 759-771.	1.4	75
45	Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Letters, 2003, 190, 73-77.	7.2	73
46	Mediterranean Diet in Predementia and Dementia Syndromes. Current Alzheimer Research, 2011, 8, 520-542.	1.4	73
47	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nature Reviews Neurology, 2020, 16, 213-228.	10.1	73
48	Sex Differences in the Association of Apolipoprotein E and Angiotensin-Converting Enzyme Gene Polymorphisms With Healthy Aging and Longevity: A Population-Based Study From Southern Italy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 918-923.	3.6	70
49	The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear. Frontiers in Neuroscience, 2019, 13, 619.	2.8	70
50	Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?. Journal of Alzheimer's Disease, 2010, 21, 57-63.	2.6	69
51	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231881100.	2.5	68
52	Metabolic Syndrome, Mild Cognitive Impairment and Dementia. Current Alzheimer Research, 2011, 8, 492-509.	1.4	67
53	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. Frontiers in Aging Neuroscience, 2015, 7, 113.	3.4	67
54	Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. International Journal of Cancer, 2001, 95, 364-369.	5.1	66

#	Article	IF	Citations
55	BACE inhibitors in clinical development for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	2.8	66
56	Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimerâ€™s disease and mild cognitive impairment. Scientific Reports, 2019, 9, 20009.	3.3	66
57	REVIEW: Î³â€Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. CNS Neuroscience and Therapeutics, 2010, 16, 272-284.	3.9	63
58	Role of the 5-HTTLPR and SNP Promoter Polymorphisms on Serotonin Transporter Gene Expression: a Closer Look at Genetic Architecture and In Vitro Functional Studies of Common and Uncommon Allelic Variants. Molecular Neurobiology, 2016, 53, 5510-5526.	4.0	63
59	Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenetics and Genomics, 2011, 21, 225-230.	1.5	62
60	Tau-based therapeutics for Alzheimerâ€™s disease: active and passive immunotherapy. Immunotherapy, 2016, 8, 1119-1134.	2.0	61
61	Information and Communication Technologies for the Activities of Daily Living in Older Patients with Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2017, 57, 927-935.	2.6	60
62	Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients. Neurobiology of Aging, 2003, 24, 933-939.	3.1	58
63	Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. Ageing Research Reviews, 2012, 11, 87-103.	10.9	57
64	Anti-amyloid-Î² protein agents for the treatment of Alzheimerâ€™s disease: an update on emerging drugs. Expert Opinion on Emerging Drugs, 2020, 25, 319-335.	2.4	57
65	The Prevalence of Diarrhea and Its Association With Drug Use in Elderly Outpatients: A Multicenter Study. American Journal of Gastroenterology, 2008, 103, 2816-2823.	0.4	56
66	The RELN Locus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 335-344.	2.6	56
67	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
68	Emerging drugs to reduce abnormal Î²-amyloid protein in Alzheimerâ€™s disease patients. Expert Opinion on Emerging Drugs, 2016, 21, 377-391.	2.4	54
69	Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Research Reviews, 2010, 9, 457-474.	10.9	53
70	Bapineuzumab: anti-Î²-amyloid monoclonal antibodies for the treatment of Alzheimerâ€™s disease. Immunotherapy, 2010, 2, 767-782.	2.0	52
71	Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	1.4	51
72	Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. Age, 2012, 34, 507-517.	3.0	51

#	Article	IF	Citations
73	Coffee Consumption Habits and the Risk ofÂMild Cognitive Impairment: The Italian Longitudinal Study on Aging. Journal of Alzheimer's Disease, 2015, 47, 889-899.	2.6	51
74	Are antibodies directed against amyloid-Î² (AÎ²) oligomers the last call for the AÎ² hypothesis of Alzheimer's disease?. Immunotherapy, 2019, 11, 3-6.	2.0	50
75	Systemic Oxidative Stress and Conversion to Dementia of Elderly Patients with Mild Cognitive Impairment. BioMed Research International, 2014, 2014, 1-7.	1.9	49
76	Beyond the neurotransmitter-focused approach in treating Alzheimerâ€™s Disease: drugs targeting Î²-amyloid and tau protein. Aging Clinical and Experimental Research, 2009, 21, 386-406.	2.9	47
77	Frailty, Disability and Physical Exercise in the Aging Process and in Chronic Kidney Disease. Kidney and Blood Pressure Research, 2014, 39, 164-168.	2.0	47
78	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. Alzheimer's and Dementia, 2019, 15, 1019-1028.	0.8	47
79	Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Research Reviews, 2009, 8, 214-236.	10.9	46
80	Advances in the identification of Î³-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opinion on Drug Discovery, 2012, 7, 19-37.	5.0	45
81	Serum paraoxonase and arylesterase activities of paraoxonaseâ€1 (<scp>PON</scp>â€1), mild cognitive impairment, and 2â€year conversion to dementia: A pilot study. Journal of Neurochemistry, 2015, 135, 395-401.	3.9	45
82	Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome. Journal of Alzheimer's Disease, 2012, 30, S31-S75.	2.6	44
83	Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiology of Aging, 2005, 26, 455-464.	3.1	43
84	A combined analytical approach reveals novelEXT1/2 gene mutations in a large cohort of Italian multiple osteochondromas patients. Genes Chromosomes and Cancer, 2007, 46, 470-477.	2.8	43
85	Progresses in treating agitation: a major clinical challenge in Alzheimerâ€™s disease. Expert Opinion on Pharmacotherapy, 2015, 16, 2581-2588.	1.8	43
86	Pharmacotherapy for the treatment of depression in patients with alzheimerâ€™s disease: a treatment-resistant depressive disorder. Expert Opinion on Pharmacotherapy, 2018, 19, 823-842.	1.8	43
87	Efficacy and safety studies of gantenerumab in patients with Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 973-986.	2.8	42
88	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. Journal of Alzheimer's Disease, 2018, 65, 989-1000.	2.6	42
89	Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	2.6	42
90	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. Journal of Alzheimer's Disease, 2017, 59, 121-130.	2.6	41

#	Article	IF	Citations
91	Monoclonal antibodies against Î²-amyloid (AÎ²) for the treatment of Alzheimer's disease: the AÎ² target at a crossroads. Expert Opinion on Biological Therapy, 2011, 11, 679-686.	3.1	40
92	Cognitive frailty: a potential target for secondary prevention of dementia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1023-1027.	3.3	40
93	Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. PLoS ONE, 2018, 13, e0193867.	2.5	40
94	Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study. Nutrients, 2020, 12, 426.	4.1	40
95	Emerging biomarkers and screening for cognitive frailty. Aging Clinical and Experimental Research, 2017, 29, 1075-1086.	2.9	39
96	Ageâ€Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy. Otolaryngology - Head and Neck Surgery, 2020, 163, 348-355.	1.9	39
97	Looking Beyond the 5-HTTLPR Polymorphism: Genetic and Epigenetic Layers of Regulation Affecting the Serotonin Transporter Gene Expression. Molecular Neurobiology, 2017, 54, 8386-8403.	4.0	38
98	Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review. Current Drug Targets, 2017, 18, 1487-1498.	2.1	38
99	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. Journal of Alzheimer's Disease, 2018, 64, S229-S254.	2.6	38
100	Genetic Profile, Environmental Exposure, and Their Interaction in Parkinsonâ€™s Disease. Parkinson's Disease, 2016, 2016, 1-9.	1.1	36
101	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	3.0	36
102	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 273.	4.8	36
103	Usefulness of the Comprehensive Geriatric Assessment in Older Patients with Upper Gastrointestinal Bleeding: A Two-Year Follow-Up Study. Digestive Diseases, 2007, 25, 124-128.	1.9	35
104	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age, 2013, 35, 441-453.	3.0	35
105	Tau-directed approaches for the treatment of Alzheimerâ€™s disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	2.8	35
106	Simple and Effective Determination of Apolipoprotein E Genotypes by Positive/Negative Polymerase Chain Reaction Products. Diagnostic Molecular Pathology, 2006, 15, 180-185.	2.1	34
107	The potential of solanezumab and gantenerumab to prevent Alzheimerâ€™s disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy, 2018, 18, 25-35.	3.1	34
108	A G-to-A mutation in IVS-3 of the human gamma fibrinogen gene causing afibrinogenemia due to abnormal RNA splicing. Blood, 2000, 96, 2501-2505.	1.4	33

#	Article	IF	Citations
109	Accumulation of Human Apolipoprotein-E in Rat Plasma After in vivo Intramuscular Injection of Naked DNA. Biochemical and Biophysical Research Communications, 1994, 200, 298-305.	2.1	32
110	Relevance of Interleukin-1 Receptor Antagonist Intron-2 Polymorphism in Ischemic Stroke. Cerebrovascular Diseases, 2003, 15, 276-281.	1.7	31
111	Neurocognitive Disorders and Dehydration in Older Patients: Clinical Experience Supports the Hydromolecular Hypothesis of Dementia. Nutrients, 2018, 10, 562.	4.1	31
112	Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimerâ€™s disease. GeroScience, 2020, 42, 159-167.	4.6	31
113	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 561.	2.2	31
114	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
115	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	7.9	30
116	Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. Journal of the Neurological Sciences, 2006, 247, 187-191.	0.6	29
117	The complex interaction between APOE promoter and AD: an Italian caseâ€“control study. European Journal of Human Genetics, 2009, 17, 938-945.	2.8	29
118	The Role of Biomarkers in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1118, 135-162.	1.6	29
119	Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder. Molecular Neurobiology, 2017, 54, 1340-1351.	4.0	28
120	Stability and functional effectiveness of phosphorothioate modified duplex DNA and synthetic â€˜mini-genesâ€™. Nucleic Acids Research, 1995, 23, 4134-4142.	14.5	27
121	Interleukin 6â€“174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 177-182.	4.8	27
122	The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. International Journal of Geriatric Psychiatry, 2011, 26, 1062-1070.	2.7	27
123	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. Neuroscience and Biobehavioral Reviews, 2018, 95, 480-498.	6.1	27
124	Apolipoprotein E Genotypes in Hospitalized Elderly Patients with Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2007, 23, 327-333.	1.5	26
125	Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation. Current Medicinal Chemistry, 2011, 18, 5430-5447.	2.4	26
126	Effectiveness of the Frequency Rhythmic Electrical Modulation System for the Treatment of Chronic and Painful Venous Leg Ulcers in Older Adults. Rejuvenation Research, 2012, 15, 281-287.	1.8	26

#	Article	IF	Citations
127	Delusions in Patients with Alzheimerâ€™s Disease: A Multidimensional Approach. Journal of Alzheimer's Disease, 2016, 51, 427-437.	2.6	26
128	CYP2D6 genotypes in revolving door patients with bipolar disorders. Medicine (United States), 2018, 97, e11998.	1.0	26
129	Klotho at the Edge of Alzheimerâ€™s Disease and Senile Depression. Molecular Neurobiology, 2019, 56, 1908-1920.	4.0	26
130	Lipoproteins, Vascular-Related Genetic Factors, and Human Longevity. Rejuvenation Research, 2007, 10, 441-458.	1.8	25
131	The APOE Gene Locus in Frontotemporal Dementia and Primary Progressive Aphasia. Archives of Neurology, 2011, 68, 622-8.	4.5	25
132	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. Rejuvenation Research, 2018, 21, 3-14.	1.8	25
133	Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. Alzheimer's and Dementia, 2017, 13, 858-869.	0.8	24
134	Polymorphisms in GlutathioneS-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease. Rejuvenation Research, 2010, 13, 645-652.	1.8	23
135	Measuring pharmacogenetics in special groups: geriatrics. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1073-1088.	3.3	23
136	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. Journal of Alzheimer's Disease, 2016, 55, 973-979.	2.6	23
137	DNA end binding activity and Ku70/80 heterodimer expression in human colorectal tumor. World Journal of Gastroenterology, 2005, 11, 6694.	3.3	23
138	Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. Gene Therapy, 2000, 7, 1795-1801.	4.5	22
139	Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochemical and Biophysical Research Communications, 2008, 370, 279-284.	2.1	22
140	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. Journal of Alzheimer's Disease, 2016, 53, 981-989.	2.6	22
141	The Missing ApoE Allele. Annals of Human Genetics, 2007, 71, 496-500.	0.8	21
142	Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial. Journal of Orthopaedic and Sports Physical Therapy, 2016, 46, 714-725.	3.5	21
143	Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12065.	3.7	21
144	Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease. Scientific Reports, 2020, 10, 14980.	3.3	21

#	Article	IF	Citations
145	Association Analysis of <i>GRIN2B</i>, Encoding N-Methyl-<i>D</i>-Aspartate Receptor 2B Subunit, and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 287-292.	1.5	20
146	PLASMA LIPID DISTURBANCES AND COGNITIVE DECLINE. Journal of the American Geriatrics Society, 2010, 58, 2429-2430.	2.6	20
147	Treatment of Late-Life Major Depressive Disorder With Selective Serotonin Reuptake Inhibitors Improves the Multidimensional Prognostic Index. Journal of Clinical Psychopharmacology, 2012, 32, 726-729.	1.4	20
148	TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2012, 31, 731-740.	2.6	20
149	Ext-mutation analysis in Italian sporadic and hereditary osteochondromas. International Journal of Cancer, 2001, 95, 378-383.	5.1	19
150	Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World Journal of Gastroenterology, 2007, 13, 4467.	3.3	19
151	An association study between epicardial fat thickness and cognitive impairment in the elderly. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1269-H1276.	3.2	19
152	Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. European Journal of Neurology, 2016, 23, 1117-1125.	3.3	19
153	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. International Psychogeriatrics, 2016, 28, 1111-1124.	1.0	19
154	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 4333-4344.	4.0	19
155	Plasma Î²-amyloid 1â€“42 reference values in cognitively normal subjects. Journal of the Neurological Sciences, 2018, 391, 120-126.	0.6	19
156	Short arm of chromosome 11 and sporadic Alzheimer's disease: Catalase and cathepsin D gene polymorphisms. Neuroscience Letters, 2008, 432, 237-242.	2.1	18
157	Psychotic Symptoms in Alzheimer's Disease and 5-HTTLPR Polymorphism of the Serotonin Transporter Gene: Evidence for an Association. Journal of Alzheimer's Disease, 2009, 16, 173-180.	2.6	18
158	Higher total cholesterol, cognitive decline, and dementia. Neurobiology of Aging, 2009, 30, 546-548.	3.1	18
159	Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. International Journal of Alzheimer's Disease, 2011, 2011, 1-14.	2.0	18
160	Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. Journal of Psychopharmacology, 2015, 29, 623-633.	4.0	18
161	Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. Journal of the Neurological Sciences, 2017, 378, 182-186.	0.6	18
162	Codon 129 polymorphism of prion protein gene in sporadic Alzheimerâ€™s disease. European Journal of Neurology, 2008, 15, 173-178.	3.3	17

#	Article	IF	Citations
163	Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice. Current Drug Metabolism, 2011, 12, 621-634.	1.2	17
164	Effects of hypercapnia on peripheral vascular reactivity in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. Clinical Interventions in Aging, 2014, 9, 871.	2.9	17
165	Tau aggregation inhibitors: the future of Alzheimerâ€™s pharmacotherapy?. Expert Opinion on Pharmacotherapy, 2016, 17, 457-461.	1.8	17
166	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimerâ€™s Disease Versus Vascular Dementia. Journal of Alzheimer's Disease, 2018, 62, 699-711.	2.6	17
167	FOXP2, APOE, and PRNP: New Modulators in Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2012, 28, 941-950.	2.6	16
168	Nutrition, frailty, and Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 221.	3.4	16
169	Apolipoprotein E Genotype in Sporadic Early- and Late-Onset Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 1998, 9, 121-125.	1.5	15
170	Apoe Ïµ2â€Ïµ4 genotype is a possible risk factor for primary progressive aphasia. Annals of Neurology, 2006, 59, 436-437.	5.3	15
171	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. Expert Opinion on Pharmacotherapy, 2019, 20, 1091-1107.	1.8	15
172	Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Review of Neurotherapeutics, 2019, 19, 397-408.	2.8	15
173	The Apolipoprotein E genotype in patients affected by syndromes with focal cortical atrophy. Neuroscience Letters, 2001, 303, 87-90.	2.1	13
174	Lack of association between genetic variants in the mannose-binding lectin 2 (MBL2) gene and HPV infection. European Journal of Epidemiology, 2007, 22, 159-162.	5.7	13
175	FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer’s disease. Clinical Interventions in Aging, 2014, 9, 1783.	2.9	13
176	Functional genetic variation in the serotonin 5-HTTLPR modulates brain damage in frontotemporal dementia. Neurobiology of Aging, 2015, 36, 446-451.	3.1	13
177	Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinsonâ€™s Disease? The Potential Role of Zolpidem in the Treatment of Parkinsonâ€™s Disease. Parkinson's Disease, 2016, 2016, 1-14.	1.1	13
178	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 259-277.	3.3	13
179	Late-Life Depression versus Amnestic Mild Cognitive Impairment: Alzheimerâ€™s Disease Incidence in 4 Years of Follow-Up. Dementia and Geriatric Cognitive Disorders, 2018, 46, 140-153.	1.5	13
180	Clinical and demographic parameters predict the progression from mild cognitive impairment to dementia in elderly patients. Aging Clinical and Experimental Research, 2021, 33, 1895-1902.	2.9	13

#	Article	IF	Citations
181	Genetic variation in MME in relation to neprilysin protein and enzyme activity, AÎ² levels, and Alzheimer's disease risk. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 30-8.	0.4	13
182	Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clinical Laboratory, 2011, 57, 887-93.	0.5	13
183	Undercoding of Alzheimer's disease and related dementias in hospitalized elderly patients in Italy. American Journal of Alzheimer's Disease and Other Dementias, 2005, 20, 167-170.	1.9	12
184	Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 867-870.	2.6	12
185	Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment. Pain Medicine, 2015, 16, 2012-2023.	1.9	12
186	Identification of a Possible Somatic BRCA1 Mutation Affecting Translation Efficiency in an Early-Onset Sporadic Breast Cancer Patient. Journal of the National Cancer Institute, 1998, 90, 1011-1012.	6.3	11
187	Differential Modulation of Ku70/80 DNA-Binding Activity in a Patient with Multiple Basal Cell Carcinomas. Journal of Investigative Dermatology, 2003, 121, 628-633.	0.7	11
188	APOLIPOPROTEIN E GENOTYPES IN MILD COGNITIVE IMPAIRMENT SUBTYPES. Journal of the American Geriatrics Society, 2006, 54, 1965-1966.	2.6	11
189	Survival in Alzheimerâ€™s Disease Is Shorter in Women Carrying Heterozygosity at Codon 129 of the <i>PRNP</i> Gene and No APOE Îµ4 Allele. Dementia and Geriatric Cognitive Disorders, 2008, 25, 354-358.	1.5	11
190	Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1518-1520.	3.1	11
191	Postural and Balance Disorders in Patients with Parkinsonâ€™s Disease: A Prospective Open-Label Feasibility Study with Two Months of Action Observation Treatment. Parkinson's Disease, 2015, 2015, 1-7.	1.1	11
192	Erythrocyte Associated Amyloid-Î² as Potential Biomarker to Diagnose Dementia. Current Alzheimer Research, 2018, 15, 381-385.	1.4	11
193	Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease. Neuroscience Letters, 2008, 438, 335-339.	2.1	10
194	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics, 2016, 16, 1357-1369.	2.8	10
195	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 843-846.	3.3	10
196	Pharmacogenetics in older people: what we know and what we need to know. Journal of Nephrology, 2012, 25, 38-47.	2.0	10
197	DIET, CHOLESTEROL METABOLISM, AND ALZHEIMER'S DISEASE: APOLIPOPROTEIN E AS A POSSIBLE LINK?. Journal of the American Geriatrics Society, 2006, 54, 1963-1965.	2.6	9
198	APOE Îµ2/Îµ4 Genotype a Risk Factor for Primary Progressive Aphasia in Women. Archives of Neurology, 2009, 66, 910-2.	4.5	9

#	Article	IF	Citations
199	Klotho locus, metabolic traits, and serum hemoglobin in hospitalized older patients: a genetic association analysis. Age, 2012, 34, 949-968.	3.0	8
200	The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2013, 21, 67-77.	1.2	8
201	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. Expert Opinion on Drug Safety, 2017, 16, 1373-1385.	2.4	8
202	Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimerâ€™s Disease. Disease Markers, 2018, 2018, 1-9.	1.3	8
203	LRP-1 variation is not associated with risk of Alzheimer's disease. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 104-13.	0.4	8
204	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimerâ€™s disease?. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210816.	2.5	8
205	APOLIPOPROTEIN E, DEMENTIA, AND HUMAN LONGEVITY. Journal of the American Geriatrics Society, 2009, 57, 740-742.	2.6	7
206	A Plasmid Family Containing Two Different Expression Cassettes Suitable for Immunomodulation and Genetic Immunization. Plasmid, 1998, 40, 84-89.	1.4	6
207	Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages. Atherosclerosis, 2007, 193, 455-457.	0.8	6
208	Association of Apolipoprotein E and Angiotensin Converting Enzyme Gene Polymorphisms with the Multidimensional Impairment in Older Patients. Rejuvenation Research, 2009, 12, 239-247.	1.8	6
209	Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia. Journal of Alzheimer's Disease, 2010, 21, 1179-1183.	2.6	6
210	Polymorphism C in the Serotonin Transporter Gene in Depression-Free Elderly Patients with Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2010, 29, 424-431.	1.5	6
211	Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. Age, 2011, 33, 409-419.	3.0	6
212	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. Expert Review of Precision Medicine and Drug Development, 2016, 1, 431-442.	0.7	6
213	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. GeroScience, 2021, 43, 1003-1014.	4.6	6
214	Absence of apolipoprotein B3500 mutation in type 2a hyperlipoproteinemia patients and in the general population from Southern Italy. Journal of Inherited Metabolic Disease, 1999, 22, 670-671.	3.6	5
215	ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. Biochemical and Biophysical Research Communications, 2007, 361, 543-548.	2.1	5
216	Apolipoprotein E-related all-cause mortality in hospitalized elderly patients. Age, 2010, 32, 411-420.	3.0	5

#	Article	IF	Citations
217	Dietary Patterns and Protection Against Alzheimer Disease and Cognitive Decline. Archives of Neurology, 2010, 67, 1285.	4.5	5
218	Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimerâ€™s disease. Translational Neurodegeneration, 2019, 8, 4.	8.0	5
219	PLASMA LEVELS OF Nâ€3 POLYUNSATURATED FATTY ACIDS AND COGNITIVE DECLINE: POSSIBLE ROLE OF DEPRESSIVE SYMPTOMS AND APOLIPOPROTEIN E GENOTYPING. Journal of the American Geriatrics Society, 2010, 58, 2249-2251.	2.6	4
220	Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials. Frontiers of Neurology and Neuroscience, 2016, 39, 124-135.	2.8	4
221	Can pharmacotherapy effectively reduce Alzheimerâ€™s related agitation?. Expert Opinion on Pharmacotherapy, 2020, 21, 1517-1522.	1.8	4
222	A New Presenilin 1 (Psen1) Mutation (p.Cys263Trp) as a Cause of Both Early and Late-Onset Alzheimerâ€™s Disease in a Large Italian Family. International Journal of Molecular Sciences, 2021, 22, 6215.	4.1	4
223	Serum Apo J as a potential marker of conversion from mild cognitive impairment to dementia. Journal of the Neurological Sciences, 2021, 427, 117537.	0.6	4
224	Serum Beta Secretase 1 (BACE1) activity increases in patients with mild cognitive impairment. Journal of Neurochemistry, 2021, 159, 629-637.	3.9	4
225	Role of the APOE polymorphism in carotid and lower limb revascularization: A prospective study from Southern Italy. PLoS ONE, 2017, 12, e0171055.	2.5	4
226	The Challenge of Antidepressant Therapeutics in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1260, 267-281.	1.6	4
227	POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENTâ€“NO DEMENTIA. Journal of the American Geriatrics Society, 2009, 57, 943-944.	2.6	3
228	Efficacy and Safety of Long-Term Administration of Tapentadol in Relieving Chronic Pancreatitis Pain. Pain Medicine, 2016, 18, pnw220.	1.9	3
229	Analysis of MTNR1B gene polymorphisms in relationship with IRS2 gene variants, epicardial fat thickness, glucose homeostasis and cognitive performance in the elderly. Chronobiology International, 2017, 34, 1083-1093.	2.0	3
230	Contribution of Mediterranean Diet in the Prevention of Alzheimerâ€™s Disease. , 2018, , 139-155.		3
231	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. Psychiatry Research, 2022, 308, 114346.	3.3	3
232	Statistical parametric mapping of FDG-PET in Alzheimer disease. , 2011, , .		2
233	Î³-secretase inhibitors for treating Alzheimerâ€™s disease: rationale and clinical data. Clinical Investigation, 2011, 1, 1175-1194.	0.0	2
234	Cognitive frailty. , 2021, , 463-476.		2

#	Article	IF	Citations
235	Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkinâ€™s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. Supportive Care in Cancer, 2022, 30, 1521-1527.	2.2	2
236	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimerâ€™s disease patients. Future Neurology, 2012, 7, 395-401.	0.5	1
237	To translate pharmacogenetics in geriatrics: towards a personalized medicine. Geriatric Care, 2015, 1, .	0.2	1
238	Genetics of tailored medicine: Focus on CNS drugs. Microchemical Journal, 2018, 136, 164-169.	4.5	1
239	Corrigendum to â€œThe Apolipoprotein E genotype in patients affected by syndromes with focal cortical atrophyâ€•[Neurosci. Lett. 303 (2001) 87â€“90]. Neuroscience Letters, 2001, 308, 66.	2.1	0
240	Response to Kittisupamongkol. American Journal of Gastroenterology, 2009, 104, 1321-1321.	0.4	0
241	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 751-765.	3.3	0
242	Delusions in dementias. , 2020, , 647-664.		0